Your browser doesn't support javascript.
loading
TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
Ishikawa, Takashi; Hara, Hiroe; Kawano, Ayumi; Tohyama, Kimio; Kajita, Yuichi; Miyanohana, Yuhei; Koike, Tatsuki; Kimura, Haruhide.
Afiliação
  • Ishikawa T; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Hara H; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Kawano A; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Tohyama K; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Kajita Y; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Miyanohana Y; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Koike T; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Kimura H; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan haruhide.kimura@takeda.com.
J Pharmacol Exp Ther ; 385(3): 193-204, 2023 06.
Article em En | MEDLINE | ID: mdl-37001988
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cataplexia / Narcolepsia Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cataplexia / Narcolepsia Idioma: En Ano de publicação: 2023 Tipo de documento: Article